Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma

Launched by SHANGHAI 6TH PEOPLE'S HOSPITAL · Aug 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for osteosarcoma, a type of bone cancer. The researchers want to find out if a combination of two medications, cisplatin and rh-endostatin (Endostar), administered directly into the arteries (a method called intra-arterial treatment), is safe and effective. They aim to see if this treatment can help reduce tumors more effectively than traditional chemotherapy alone. Patients who participate will receive this new treatment along with standard chemotherapy, which includes drugs like methotrexate and adriamycin, every 2-3 weeks for 2-4 cycles before any surgery.

To be eligible for this trial, participants should be between 18 to 40 years old and have a confirmed diagnosis of osteosarcoma. They must agree to follow the treatment plan and provide detailed medical information. However, individuals with certain health issues, such as severe liver or kidney problems, recent injuries or infections, or specific other medical conditions, may not be able to join the study. Overall, this trial offers a potential new option for young adults facing osteosarcoma, and researchers are eager to learn more about how well this combination treatment works.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically or cytologically confirmed diagnosis of osteosarcoma patients aged 18-40 years old;
• • 2. Accept to receive treatment with neoadjuvant chemotherapy regimen and completing the standard treatment course; Voluntary informed consent, joining the study with good compliance.
• • 3. Have detailed medical data (such as medical history data, laboratory reports of blood routine and liver and kidney functions, pathology reports, etc.), and complete records of postoperative follow-up.
• Exclusion Criteria:
• • 1. Combined history of acute injury, infection and surgery in the last 3 months;
• • 2. Those with severe liver and kidney function abnormalities;
• • 3. Those who are using anti-inflammatory drugs;
• • 4. Pre-existing hematologic diseases before treatment;
• • 5. Combined with other malignant tumors;
• • 6. Diagnosed with autoimmune disease or using steroid drugs for more than 1 month before treatment;
• • 7. Suffering from mental illness or cognitive dysfunction.